Patent intelligence · US
US 11806400
Injectable ibuprofen formulation
Injectable ibuprofen formulation
Patent details — US 11806400
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 7, 2023
- Expiration
- Nov 2, 2043
- Applicant
- Cumberland Pharmaceuticals Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/192, A61K47/02, A61P
Quick answer
US 11806400 (Injectable ibuprofen formulation) is held by Cumberland Pharmaceuticals Inc.. Status: granted. Granted Nov 7, 2023. Expires Nov 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cumberland Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/192, A61K47/02, A61P, A61P29/00, A61P9/00
More from Cumberland Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12161632
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 11571412
Thromboxane receptor antagonists in AERD/asthma
granted -
US 10925860
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 10751383
Doses and methods for administering telavancin
granted -
US 10583126
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 10456380
Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
granted -
US 10314824
Compositions and methods of treating cardiac fibrosis with ifetroban
granted
Frequently asked questions
What is US patent 11806400?
US 11806400 (Injectable ibuprofen formulation) is held by Cumberland Pharmaceuticals Inc.. Status: granted. Granted Nov 7, 2023. Expires Nov 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11806400?
Cumberland Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 11806400 expire?
Our index shows an expiration date of Nov 2, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.